MDxHealth SA(MDXH) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:31 AM ET (Korea 10/28 17:31)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.73 | Insider Own | 31.9% | Shs Outstand | 95.4M | Perf Week | 1.34% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | 44.08% | Insider Trans | 7.8% | Shs Float | 65.0M | Perf Month | -64.05% |
| Enterprise Value | 0.11B | PEG | - | EPS next Q | -0.09 | Inst Own | 37.04% | Short Float | 1.84% | Perf Quarter | -50.77% |
| Income | -0.04B | P/S | 0.17 | EPS this Y | 24.38% | Inst Trans | 46.85% | Short Ratio | 0.2 | Perf Half Y | -90.34% |
| Sales | 0.11B | P/B | - | EPS next 5Y | 40.66% | ROA | -25.87% | Short Interest | 1.19M | Perf YTD | -94.48% |
| Book/sh | -0.59 | P/C | 0.98 | EPS past 3/5Y | 37.71% 27.91% | ROE | -2440.41% | 52W High | -96.3% ($5.33) | Perf Year | -95.89% |
| Cash/sh | 0.2 | P/FCF | - | Sales past 3/5Y | 42.79% 42.48% | ROIC | -50.7% | 52W Low | 15.2% ($0.17) | Perf 3Y | -91.47% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.23% | Gross Margin | 59.15% | Volatility(W/M) | 14.57% 15.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 0.95 | Sales Y/Y TTM | 12.75% | Oper. Margin | -19.01% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.98 | EPS Q/Q | -50.77% | Profit Margin | -33.46% | RSI (14) | 24.53 | Recom | 2.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.15 | Sales Q/Q | 2.27% | SMA20 | -55% ($0.44) | Beta | 0.75 | Target Price | $1.12 |
| Payout | - | Debt/Eq | - | Earnings | 2026/11/12 | SMA50 | -66.33% ($0.59) | Rel Volume | 0.09 | Prev Close | $0.19 |
| Employees | 364 | LT Debt/Eq | - | EPS/Sales Surpr. | 6.93% 4.07% | SMA200 | -87.5% ($1.6) | Avg Volume(3M) | 6.05M | Price | $0.2 |
| IPO | 2021/11/4 | Option/Short | No/Yes | Trades | 537 | Volume | 543,102 | Change | 1.18% |
A global healthcare company that provides innovative molecular diagnostic solutions for the precise diagnosis of urological diseases. It possesses genetic testing technologies for the early diagnosis and prognostic prediction of prostate cancer and is building a precision medicine ecosystem that helps support patient-tailored treatment decisions.
Over the past 1 year, on the lower side
96% below its 1-year high.
Traded less than usual. That is 9% of its average volume.
Next earnings report: November 12
MDXH has weak earning power
Of every $100 in sales, $19.01 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.4% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $17. Peers typically go for $451.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -91.5%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 37.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IWC iShares Micro-Cap ETF <0.01% It ranks #39 of 44 in the industry
Based on market cap of $19M.
PRPO#38 Precipio Inc $34M PER - MDXH#39 MDxHealth SA $19M PER - 
NDRA#40 ENDRA Life Sciences Inc $7M PER - 
XWEL#41 XWELL Inc $7M PER - 
ADVB#42 Advanced Biomed Inc $5M PER - 
FAQ
What kind of company is MDXH?
MDXH belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of MDXH?
The market cap of MDXH is approximately $19M, ranking 5,228 within its sector.
What is the 52-week high and low for MDXH?
MDXH has recorded a 52-week high of $5.33 and a low of $0.17.
